Together these results suggest that BZA retains its SERM antagonist properties within breast cancer cells expressing Y537S and D538G mutant ERα to a greater extent than 4-OHT but its SERD-like properties are diminished. The gene discussed is ESR1; the disease is breast carcinoma.